David H Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared a post on X:
“Biomarker-Directed Trials in Advanced/Metastatic Urothelial Cancer at MSKCC
FORAGER-1 – Next-generation FGFR3 inhibitor LOXO-435
- Front-line: EV + pembrolizumab + LOXO-435
- Treatment-refractory FGFR3-mutant mUC: LOXO-435 monotherapy
- Requires early cell-free DNA testing to confirm FGFR3 alteration (driver mutation or fusion)
A Phase 1a Study of LOXO-435 in People with Advanced Solid Tumors Containing FGFR3 Gene Changes
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 (FORAGER-1)
HER2-positive (IHC 1/2/3+) mUC – Disitamab Vedotin (DV)
- Front-line: DV + Pembrolizumab vs DV
- Post-EV/platinum: DV monotherapy post EV+/-P
A Phase 2 Study of Disitamab Vedotin Alone and with Pembrolizumab Immunotherapy in People with Inoperable or Metastatic Urothelial Cancer
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
PPAR-γ–High UC – FX-909 (PPAR-γ inhibitor)
- Targeted therapy for PPAR-γ–high metastatic UC
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma”
More posts featuring David H Aggen.